Jorge Field-Cortazares, Departamento de Pediatría e Infectología, Universidad Autónoma de Baja California, Ensenada, Baja California, México
José J. Coria-Lorenzo, Servicio de Infectología, Hospital Infantil de México Federico Gómez, Ciudad de México, México
Débora Domingo-Martínez, Departamento de Neurología, Hospital Infantil de México Federico Gómez, Ciudad de México, México
Luis E. Moctezuma-Paz, Departamento de Capacitación, Sección II del Sindicato Nacional de Trabajadores del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México. México
Objective: To evaluate if the comorbidity and coinfections presented by SARS-CoV-2 infection vs. COVID-19 impact our Mexican children. Method: Prospective and observational study that included the 2020-2021 peak influenza season. All patients with a diagnosis of infection by SARS-CoV-2 vs. COVID-19 who were admitted to the Hospital Infantil de Mexico were analyzed. Real-time RT-PCR for SARS-CoV-2 was performed in all patients, determining E, RdRp and RP genes and protein N, as well as RT-PCR for detection of respiratory viruses. Results: The inclusion criteria were met by 163 patients. The group with the highest risk of becoming ill was adolescents (40.4%), followed by schoolchildren and preschoolers (21.4% and 19.6% of the cases, respectively). There were three cases with viral coinfection: two (1.2%) with parvovirus B-19 and one (0.6%) with herpes type I; another two (1.2%) showed bacterial coinfection. The main comorbidity were obesity, acute lymphoblastic leukemia and arterial hypertension. Regarding mortality, we only had four cases (2.4%). Conclusions: Obesity, cancer, hypertension, heart disease and diabetes are comorbidity present in our patients, as referred to in literature, but not coinfections. In our study, we did not have any associated mortality related to comorbidity.
Keywords: SARS-CoV-2. COVID-19. Coinfections. Comorbidity. Morbidity. Mortality.